Clinical Trials · NCT02276196
Effect of LIXIsenatide on the Renal System
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Amsterdam UMC, location VUmc
- Enrollment
- 40
- Start date
- Sep 2014
- Locations
- 1 site, Netherlands
- Primary endpoint
- Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)